Addex Therapeutics reports a $1.54 million loss in Q3, contrasting a previous one-time profit.

Addex Therapeutics, a Swiss biopharmaceutical company, reported a net loss of $1.54 million in the third quarter of 2024, a significant drop from the second quarter's net profit of $12.9 million due to a one-time gain from selling part of its business. Despite this, the company's nine-month results still show a net profit of $8.3 million. The final third-quarter results will be released on November 22.

November 11, 2024
3 Articles